keyword
https://read.qxmd.com/read/38625747/the-estrogen-signaling-pathway-reprograms-prostate-cancer-cell-metabolism-and-supports-proliferation-and-disease-progression
#21
JOURNAL ARTICLE
Camille Lafront, Lucas Germain, Gabriel H Campolina-Silva, Cindy Weidmann, Line Berthiaume, Hélène Hovington, Hervé Brisson, Cynthia Jobin, Lilianne Frégeau-Proulx, Raul Cotau, Kevin Gonthier, Aurélie Lacouture, Patrick Caron, Claire Ménard, Chantal Atallah, Julie Riopel, Éva Latulippe, Alain Bergeron, Paul Toren, Chantal Guillemette, Martin Pelletier, Yves Fradet, Clémence Belleannée, Frédéric Pouliot, Louis Lacombe, Éric Lévesque, Étienne Audet-Walsh
Just as the androgen receptor (AR), the estrogen receptor α (ERα) is expressed in the prostate and is thought to influence prostate cancer (PCa) biology. Yet, the incomplete understanding of ERα functions in PCa hinders our ability to fully comprehend its clinical relevance and restricts the repurposing of estrogen-targeted therapies for the treatment of this disease. Using two human PCa tissue microarray cohorts, we first demonstrated that nuclear ERα expression was heterogeneous among patients, being only detected in half of tumors...
April 16, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38624195/network-meta-analysis-of-combination-strategies-in-metastatic-hormone-sensitive-prostate-cancer
#22
JOURNAL ARTICLE
Shan-Shan Wang, Xiao-Jie Bian, Jun-Long Wu, Bei-He Wang, Sheng Zhang, Ding-Wei Ye
This study compared different doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC). PubMed, EMBASE, and the Cochrane Library were comprehensively searched for eligible randomized controlled trials (RCTs) published from inception to October 2023. Interventions included abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), either as doublet or triplet therapies. The outcomes examined were overall survival (OS), progression-free survival (PFS), castration-resistant prostate cancer (CRPC)-free survival, time to symptomatic skeletal event (SSE), and toxicity...
April 12, 2024: Asian Journal of Andrology
https://read.qxmd.com/read/38624096/endocrinological-and-metabolic-profile-of-gaucher-disease-patients-treated-with-enzyme-replacement-therapy
#23
JOURNAL ARTICLE
Ayse Kilic, Merve Emecen Sanli, Ekin Ozsaydı Aktasoglu, Sabire Gokalp, Gürsel Biberoğlu, Aslı Inci, Ilyas Okur, Fatih Suheyl Ezgu, Leyla Tumer
OBJECTIVES: Gaucher Disease (GD) is a lysosomal storage disease caused by glucocerebrosidase (GCase) enzyme deficiency. Gaucher cells transformed from the macrophages by progressive sphingolipid accumulation and infiltrate bone marrow, spleen, liver, and other organs. The accumulation of substrate causes inflammation, compromised cellular homeostasis, and disturbed autophagy. It has been hypothesized that this proinflammatory state of GD leads cytokines and chemokines release. As a result of inflammatory process, the cellular dysfunction caused by disruption of cellular signaling, organelle dysfunction, or autoimmune antibodies may affect endocrine profile of GD patients such as hormone levels, lipid profile, and bone mineral density status...
April 17, 2024: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://read.qxmd.com/read/38623967/role-of-%C3%AE-3-subunit-of-the-gaba-type-a-receptor-in-triple-negative-breast-cancer-proliferation-migration-and-cell-cycle-progression
#24
JOURNAL ARTICLE
J Bundy, J Shaw, M Hammel, J Nguyen, C Robbins, I Mercier, A Suryanarayanan
Triple negative breast cancer (TNBC) is known for its heterogeneous nature and aggressive onset. The unresponsiveness to hormone therapies and immunotherapy and the toxicity of chemotherapeutics account for the limited treatment options for TNBC. Ion channels have emerged as possible therapeutic candidates for cancer therapy, but little is known about how ligand gated ion channels, specifically, GABA type A ligand-gated ion channel receptors (GABAA R), affect cancer pathogenesis. Our results show that the GABAA β3 subunit is expressed at higher levels in TNBC cell lines than non-tumorigenic cells, therefore contributing to the idea that limiting the GABAA R via knockdown of the GABAA β3 subunit is a potential strategy for decreasing the proliferation and migration of TNBC cells...
April 16, 2024: Cell Cycle
https://read.qxmd.com/read/38623375/isotretinoin-unresponsive-acne-as-a-sign-of-a-congenital-disorder-a-case-of-21-hydroxylase-deficiency
#25
JOURNAL ARTICLE
Elisa Marzola, Vincenzo Bettoli
Acne is a multifactorial and common disorder among young people and a frequent reason for dermatology consultation. When moderate-to-severe acne is not responsive to conventional treatments, oral isotretinoin is a very effective solution. However, there are cases in which this treatment fails to produce the expected results. In this case, an 18-year-old male patient with acne, unresponsive to traditional acne therapies, experienced only a partial benefit from oral isotretinoin. Endocrinology consultation and hormonal work-up revealed androgen metabolism anomalies suggestive of a non-classical form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency...
March 12, 2024: Dermatology Reports
https://read.qxmd.com/read/38623131/calcium-chaos-in-sarcoidosis-a-tale-of-severe-hypercalcemia-s-diagnostic-challenge
#26
Mansi Satasia, Archit Garg, Kulani Weerasinghe, Chirag Patel, Mario Caldararo
Sarcoidosis is a systemic inflammatory condition characterized by noncaseating granulomas. Lung involvement is typical, while extrapulmonary manifestations, notably lymphadenopathy, are observed in a significant proportion of cases. The etiology involves complex interactions among immune cells and mediators, resulting in granuloma formation capable of independently producing 1,25-dihydroxyvitamin D, leading to unregulated hypercalcemia and hypercalciuria. Diagnosis can be challenging, especially when hypercalcemia is the initial symptom...
March 2024: Curēus
https://read.qxmd.com/read/38622851/use-of-approved-lu-177-radiopharmaceuticals-in-patients-with-end-stage-renal-disease-a-review-of-the-literature-and-proposed-treatment-algorithm
#27
JOURNAL ARTICLE
Nikolaos A Trikalinos, Hyun Kim, Anitha Vijayan, Maxwell Amurao, Vikas Prasad
Peptide receptor radionuclide therapy (PRRT) can be a very useful treatment for patients with neuroendocrine neoplasms and metastatic castration-resistant prostate cancer but it is routinely avoided in those with advanced kidney disease because it can adversely affect the renal function. Accordingly, no clear guidelines exist on the use of PRRT for patients on hemodialysis (HD). We performed a literature review to identify publications on HD patients who received PRRT with Lutetium-177 (Lu177 ) Dotatate and Y-90 and obtained information on Lu177 pharmacokinetics and early testing data from the manufacturer...
April 15, 2024: Journal of Neuroendocrinology
https://read.qxmd.com/read/38622725/human-mesenchymal-stem-cells-derived-exosomes-improve-ovarian-function-in-chemotherapy-induced-premature-ovarian-insufficiency-mice-by-inhibiting-ferroptosis-through-nrf2-gpx4-pathway
#28
JOURNAL ARTICLE
Yuan Zhou, Jinfa Huang, Lingling Zeng, Qian Yang, Fangjuan Bai, Qiqing Mai, Kaixian Deng
BACKGROUND: Chemotherapy exposure has become a main cause of premature ovarian insufficiency (POI). This study aimed to evaluate the role and molecular mechanism of human umbilical cord mesenchymal stem cell-derived exosomes (hUMSC-Exos) in ovarian function protection after chemotherapy. METHODS: hUMSC-Exos were applied to cyclophosphamide-induced premature ovarian insufficiency mice and human ovarian granulosa tumor cells (KGN) to determine their effects on follicular development and granulosa cell apoptosis...
April 15, 2024: Journal of Ovarian Research
https://read.qxmd.com/read/38622435/predictive-value-of-postprandial-c-peptide-for-utilizing-multiple-daily-injection-therapy-in-type-2-diabetes
#29
JOURNAL ARTICLE
Wei Liu, Ying Gao, Rui Zhang, Siqian Gong, Xiangqing Wang, Yanai Wang, Xiaoling Cai, Xiuying Zhang, Xiaoqi Xie, Xueyao Han, Linong Ji
PURPOSE: Multiple daily injection (MDI) insulin therapy is an effective method of glycemic control and appropriate assignment to MDI therapy could minimize the risks of hypoglycemia and weight gain. The aim of the present study was to identify factors associated with indication for MDI therapy in type 2 diabetes (T2DM). METHODS: We recruited 360 participants with T2DM that were admitted to the Endocrinology Department of Peking University People's Hospital between August 2017 and July 2018...
April 15, 2024: Endocrine
https://read.qxmd.com/read/38621915/-mechanism-of-kuntai-capsules-in-treatment-of-polycystic-ovary-syndrome-rat-models-based-on-age-rage-signal-pathway
#30
JOURNAL ARTICLE
Jin-Ge Huang, Jian Zhang, Rui-Jun Xiang, Yuan-Yuan Wu, Tian-Yu He, Meng-Ni Zhao, Fang Wang
This study aims to investigate the impact of Kuntai Capsules(KTC) on polycystic ovarian syndrome(PCOS) rat models and explore the underlying mechanism. Fifty female SD rats were randomly divided into five groups(10 rats in each group), including control group, model group, low-, medium-, and high-dose KTC group. Except for the control group, the other groups were injected with dehydroepiandrosterone(DHEA) combined with a high-fat diet(HFD) to induce the PCOS rat model for 28 days. 0.315, 0.63, and 1.26 g·kg~(-1)·d~(-1) KTC was dissolved in the same amount of normal saline and given to low-, medium-, and high-dose KTC groups by gavage...
February 2024: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://read.qxmd.com/read/38621590/positive-interplay-between-ffar4-gpr120-dpp-iv-inhibition-and-glp-1-in-beta-cell-proliferation-and-glucose-homeostasis-in-obese-high-fat-fed-mice
#31
JOURNAL ARTICLE
A I Owolabi, R C Corbett, P R Flatt, A M McKillop
G-protein coupled receptor-120 (GPR120; FFAR4) is a free fatty acid receptor, widely researched for its glucoregulatory and insulin release activities. This study aimed to investigate the metabolic advantage of FFAR4/GPR120activation using combination therapy. C57BL/6 mice, fed a High Fat Diet (HFD) for 120 days to induce obesity-diabetes, were subsequently treated with a single daily oral dose of FFAR4/GPR120 agonist Compound A (CpdA) (0.1μmol/kg) alone or in combination with sitagliptin (50mg/kg) for 21 days...
April 13, 2024: Peptides
https://read.qxmd.com/read/38621244/oncology-what-you-may-have-missed-in-2023
#32
JOURNAL ARTICLE
Courtney H Coschi, Lorin Dodbiba, DuPont Guerry
Advances in oncology treatment methods have improved outcomes and quality of life for patients with cancer. However, care of these patients can be complex, and the contribution of physicians from different specialties is crucial. This article highlights important publications from 2023 on topics across a wide spectrum relating to the management of oncology patients. The literature was screened for significant new evidence that is relevant to internal medicine specialists and subspecialists whose focus is not oncology...
April 16, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38620054/top-advances-of-the-year-uterine-cancer
#33
JOURNAL ARTICLE
Britt K Erickson, Brian Slomovitz, Matthew Powell, Ramez N Eskander
Endometrial cancer continues to be the only gynecologic malignancy with a rising incidence and mortality, with both regional and global implications. Combination carboplatin and paclitaxel has been the recognized chemotherapy backbone for the treatment of advanced-stage or recurrent disease, with modest clinical outcomes. Over the last year, significant advances were achieved in improving oncologic outcomes by capitalizing on the molecular characterization of this heterogenous disease. These advances include incorporation of immunotherapy, identification of effective hormonal approaches, the evolution of antibody drug conjugates, and utilization of alternate targeted therapies...
April 15, 2024: Cancer
https://read.qxmd.com/read/38619605/the-cost-effectiveness-of-osteoporosis-medications-for-preventing-periprosthetic-fractures-following-femoral-neck-fracture-indicated-hip-arthroplasty-a-break-even-analysis
#34
JOURNAL ARTICLE
Amil R Agarwal, Matthew J Kinnard, Christopher Murdock, Amy Y Zhao, Uzoma Ahiarakwe, Jordan S Cohen, Kendall F Moseley, Gregory J Golladay, Savyasachi C Thakkar
UNLABELLED: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF). Our study evaluated the economic viability of treatment in patients following arthroplasty and demonstrates that treatment with oral bisphosphonates can be cost-effective in preventing PPF. INTRODUCTION: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF)...
April 15, 2024: Osteoporosis International
https://read.qxmd.com/read/38619017/fezolinetant-for-the-treatment-of-vasomotor-symptoms-associated-with-menopause-a-meta-analysis
#35
REVIEW
Matheus Pedrotti Chavez, Eric Pasqualotto, Rafael Oliva Morgado Ferreira, Alexandre Hohl, Francisco Cezar Aquino de Moraes, Pedro Henrique Siedschlag Schmidt, Anna Luíza Soares de Oliveira Rodrigues, Joao Roberto de Sa
This systematic review and meta-analysis investigated the efficacy and safety of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. PubMed, Cochrane Library, Embase and Web of Science were searched for randomized controlled trials (RCTs) published from inception to June 2023, comparing fezolinetant to placebo in postmenopausal women suffering from moderate-to-severe VMS. The mean difference and risk ratio were calculated for continuous and binary outcomes, respectively...
April 15, 2024: Climacteric: the Journal of the International Menopause Society
https://read.qxmd.com/read/38618931/experimental-and-new-investigational-drugs-for-the-treatment-of-uterine-fibroids
#36
REVIEW
Giulio Evangelisti, Simone Ferrero, Umberto Perrone, Claudio Gustavino, Eugenio Volpi, Alberto Izzotti, Fabio Barra
INTRODUCTION: Uterine fibroids, the most prevalent benign tumors among reproductive-age women, pose treatment challenges that range from surgical interventions to medical therapies for symptom control. Progestins and estroprogestins effectively manage uterine bleeding by suppressing dysfunctional endometrium over fibroids. While GnRH agonists represent a crucial milestone in symptom treatment, their prolonged use results in menopausal-like symptoms and irreversible bone mineral density loss...
April 15, 2024: Expert Opinion on Investigational Drugs
https://read.qxmd.com/read/38618919/clinical-manifestation-risk-factors-and-immune-checkpoint-inhibitor-rechallenge-of-checkpoint-inhibitor-associated-pneumonitis-in-patients-with-lung-cancer
#37
JOURNAL ARTICLE
Xuemeng Li, Fang Yang, Baogang Liu, Leiguang Ye, Jingwen Du, Xiaona Fan, Yue Yu, Mengwei Li, Li Bu, Zhuoqi Zhang, Lili Xie, Wuquan Li, Jiaqing Qi
Immune-related adverse effects can lead to damage to various systems of the body, checkpoint inhibitor-associated pneumonitis (CIP) is one of the potentially lethal immune-related adverse effects. However, evidence regarding the risk factors associated with CIP is limited. To timely and accurate identification and prompt treatment of CIP, understanding the risk factors for multimorbidity among diverse study populations becomes crucial. We retrospectively analyzed the clinical data of 1131 patients with lung cancer receiving immunotherapy to identify 110 patients with CIP, the clinical characteristics and radiographic features of patients with CIP were analyzed...
April 15, 2024: Journal of Immunotherapy
https://read.qxmd.com/read/38618281/synthesis-and-anti-diabetic-activity-of-an-8-purine-derivative-as-a-novel-dpp-4-inhibitor-in-obese-diabetic-z%C3%A3-cker-rats
#38
JOURNAL ARTICLE
Meriem Chayah, Angélica Luque-González, Verónica Gómez-Pérez, Diego Salagre, Amjad Al-Shdaifat, Joaquín María Campos, Ana Conejo-García, Ahmad Agil
Type 2 diabetes mellitus (T2DM) is one of the world's principal metabolic diseases characterized by chronic hyperglycemia. The gut incretin hormones, glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), which has been proposed as a new treatment for T2DM, are extensively metabolized by Dipeptidyl peptidase 4 (DPP-4). Inhibitors of DPP-4 block the degradation of GLP-1 and GIP and may increase their natural circulating levels, favoring glycemic control in T2DM. A novel and potent selective inhibitor of DPP-4 with an 8-purine derived structure ( 1 ) has been developed and tested in vitro and in vivo in Zücker obese diabetic fatty (ZDF) rats, an experimental model of the metabolic syndrome and T2DM to assess the inhibitory activity using vildagliptin as reference standard...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38617928/the-role-of-gender-differences-in-the-outcome-of-juvenile-social-isolation-emphasis-on-changes-in-behavioral-biochemical-and-expression-of-nitric-oxide-synthase-genes-alteration
#39
JOURNAL ARTICLE
Soroush Bijani, Fatemeh Sadat Kashfi, Sadaf Zahedi-Vanjani, Keivan Nedaei, Ali Sharafi, Ali Kalantari-Hesari, Mir-Jamal Hosseini
Social isolation can cause serious problem in performance of individuals in community. As gender differences may cause variation results in the severity of depressive behavior and response of patients to therapy, the impact of gender and the interaction of the level of endocrine secretion in depression were investigated in this study. Wistar rats of both sexes were subjected to post-weaning social isolation (PWSI) conditions and, together with the control group, experienced several behavioral tests including open-field Test (OFT), elevated plus maze (EPM), force swimming test (FST), splash test and novel object recognition test (NOR)...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38617842/therapy-for-hormone-receptor-positive-human-epidermal-growth-receptor-2-negative-metastatic-breast-cancer-following-treatment-progression-via-cdk4-6-inhibitors-a-literature-review
#40
REVIEW
Meixi Ye, Hao Xu, Jinhua Ding, Li Jiang
Endocrine therapy (ET) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the first-line standard treatment for most patients with hormone receptor-positive (HR+) and human epidermal growth receptor 2-negative (HER2-) metastatic or advanced breast cancer. However, the majority of tumors response to and eventually develop resistance to CDK4/6is. The mechanisms of resistance are poorly understood, and the optimal postprogression treatment regimens and their sequences continue to evolve in the rapidly changing treatment landscape...
2024: Breast Cancer: Targets and Therapy
keyword
keyword
12260
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.